Navigation Links
Novo Nordisk Appoints Andy Ajello as Vice President for National Diabetes Sales, Managed Care and Government Accounts

PRINCETON, N.J., Feb. 17 /PRNewswire-FirstCall/ -- Novo Nordisk, a global healthcare company focusing on diabetes care, today announced the appointment of Andy Ajello as vice president for National Diabetes Sales, Managed Care and Government Accounts. Ajello joins the Executive Team and will report directly to Jerzy Gruhn, president of Novo Nordisk's North American affiliate.

Ajello was most recently the associate vice president of Diabetes Sales for the eastern area, where he led more than 600. In his new position, he will lead the company's 2,000-person field sales organization. Ajello joined Novo Nordisk in 2001 where he helped to launch NovoLog(R) (insulin aspart [rDNA origin] injection).

"In his eight years at Novo Nordisk, Andy has developed an impressive track record for building high performing field sales teams," said Jerzy Gruhn, president of Novo Nordisk Inc. "His focus on cross-functional collaboration, quick decision-making and strategic execution will help us continue our growth and ultimately realize our ambition of changing diabetes."

Ajello has been recognized and awarded at Novo Nordisk for achievements in sales leadership, training, and marketing, including being named as the Novo Nordisk International Sales Manager of the Year in 2007. Ajello's unique style and insights into team development and management were featured in a Wall Street Journal article in 2008. Prior to Novo Nordisk, Ajello held a 10-year tenure at GlaxoSmithKline.

Ajello received a Bachelor's degree in economics from Susquehanna University.

About Novo Nordisk

Novo Nordisk is a healthcare company with an 86-year history of innovation and achievement in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition to diabetes care, Novo Nordisk has a leading position within areas such as hemostasis management, growth hormone therapy, and hormone therapy for women. Novo Nordisk's business is driven by the Triple Bottom Line: a commitment to social responsibility to employees and customers, environmental soundness and economic success. With headquarters in Denmark, Novo Nordisk employs more than 27,000 employees in 81 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For global information, visit; for United States information, visit

SOURCE Novo Nordisk
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Appoints New Leader of North American Business
2. Novo Nordisk Ranks Supersector Leader in the 2007 Dow Jones Sustainability Indexes
3. Novo Nordisk Settles With Pfizer On Patent Infringement Suit
4. Novo Nordisk Increased Net Profit by 32% in 2007
5. Novo Nordisk Files Annual Report with the SEC
6. Novo Nordisk Consolidates U.S. Diabetes Sales Leadership Under Single Vice President
7. FDA Approves NOVO NORDISKs NovoSeven(R) RT (Coagulation Factor VIIa [Recombinant] Room Temperature Stable) for Hemophilia Patients With Inhibitors
8. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
9. Novo Nordisk Makes its Debut in FORTUNEs 100 Best Companies to Work For
10. WorldHeart Appoints David Pellone Chief Financial Officer
11. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... , ... First Choice Emergency Room , the largest network of independent ... Director of its new Mesquite-Samuell Farm facility. , “We are pleased to announce ... Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from reveals that ...
(Date:6/24/2016)... ... 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out of ... verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. ... throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... Diego, CA (PRWEB) , ... June 24, 2016 , ... ... with the American Cancer Society and the Road To Recovery® program to drive cancer ... to seniors and other adults to ensure the highest quality of life and ongoing ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
Breaking Medicine Technology: